NCM · Biotechnology

NKTR (NKTR) Stock

$70.68 -0.13% NCM: NKTR Healthcare

Valuation

MetricValue
Price$70.68
Market Cap$1.38B
P/E Ratio-6.95
P/B Ratio14.67
P/S Ratio23.74
EPS (TTM)$-9.73
52-Week High$109.00
52-Week Low$8.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-182.22%
ROA-58.57%
ROCE-147.19%
Gross Margin-238.18%
Operating Margin-238.18%
Net Margin-2.84%
Debt/Equity0.25
Current Ratio4.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$102.0M$92.0M$90.0M$98.0M$55.0M
Operating Profit$-446.0M$-240.0M$-137.0M$-105.0M$-131.0M
Net Profit$-524.0M$-368.0M$-276.0M$-119.0M$-164.0M
EPS$-42.90$-29.51$-21.79$-8.68$-9.73
Op Margin-437.8%-261.0%-152.5%-106.9%-236.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$711.0M$398.0M$304.0M$280.0M
Total Liabilities$438.0M$344.0M$267.0M$243.0M$191.0M
Cash$25.0M$88.0M$35.0M$44.0M$15.0M
Borrowings$143.0M$131.0M$118.0M$103.0M$149.0M

Latest News

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema Stocktwits · Jul 3, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire · Jun 26, 2026 What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year Motley Fool · Jun 24, 2026 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal 24/7 Wall St. · Jun 23, 2026 Nektar Therapeutics Insider Sold Shares Worth $1,215,056, According to a Recent SEC Filing MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-413.0M$-304.0M$-193.0M$-176.0M$-209.0M
Investing Cash Flow$188.0M$360.0M$139.0M$141.0M$-1.0M
Financing Cash Flow$3.0M$1.0M$0$42.0M$0
Net Cash Flow$-174.0M$63.0M$-53.0M$9.0M$-29.0M
Free Cash Flow$-428.0M$-310.0M$-193.0M$-177.0M$-209.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-15.44%
Quick Ratio10.21
Interest Coverage-5.04
Return 1Y177.44%
Return 3Y772.45%
Return 5Y-73.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%

About NKTR

NKTR is led by CEO Howard W. Robin, employs 61 people, headquartered in US, publicly traded since 1994.

NKTR stock trades at $70.68 with a market capitalization of $1.38B. The stock is valued at a price-to-earnings (P/E) ratio of -6.95, price-to-book of 14.67, price-to-sales of 23.74. Over the past 52 weeks the stock has ranged between $8.35 and $109.00, and currently trades 35.2% below its 52-week high.

On profitability, NKTR generates a return on equity (ROE) of -182.22%, return on capital employed of -147.19%, an operating margin of -238.18%, a net profit margin of -2.84%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides